STA-1474
STA-1474 is an orally active and highly selective HSP90 inhibitor. STA-1474 can trigger tumor cell apoptosis. STA-1474 demonstrates significant antitumor efficacy in spontaneous canine cancer models (e.g., osteosarcoma, thyroid carcinoma) . STA-1474 is promising for research of solid tumors (e.g., osteosarcoma, breast cancer) and HSP90-driven cancers[1][2].
Product Specifications
CAS Number
1118915-78-8
UNSPSC
12352005
Target
HSP
Related Pathways
Cell Cycle/DNA Damage; Metabolic Enzyme/Protease
Field of Research
Cancer
Smiles
O=C1NN=C(C2=CC(C(C)C)=C(OP(O)(O)=O)C=C2O)N1C3=CC4=C(N(C)C=C4)C=C3
Molecular Formula
C20H21N4O6P
Molecular Weight
444.38
References & Citations
[1]McCleese JK, Bear MD, Fossey SL, Mihalek RM, Foley KP, Ying W, Barsoum J, London CA. The novel HSP90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines. Int J Cancer. 2009 Dec 15;125 (12) :2792-801.|[2]London CA, et al. Phase I evaluation of STA-1474, a prodrug of the novel HSP90 inhibitor ganetespib, in dogs with spontaneous cancer. PLoS One. 2011;6 (11) :e27018.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
HSP90
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC400257-500 1x 500 µL
Cytokeratin, HMW (AE-3), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040040-500 1x 500 µL
CD35 / CR1 (E11), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC400633-100 1x 100 µL
Von Willebrand Factor (3E2D10), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details